Skip to main content
OCULAR THERAPEUTIX, INC logo

OCULAR THERAPEUTIX, INC — Investor Relations & Filings

Ticker · OCUL ISIN · US67576A1007 LEI · 529900ABAWFXOHSIHG03 US Manufacturing
Filings indexed 801 across all filing types
Latest filing 2026-05-05 Interim / Quarterly Rep…
Country US United States of America
Listing US OCUL

About OCULAR THERAPEUTIX, INC

https://www.ocutx.com/

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. The company's primary focus is on transforming the treatment of retinal diseases, such as wet age-related macular degeneration (wet AMD), a leading cause of blindness. Ocular Therapeutix utilizes its proprietary hydrogel-based drug delivery platform, ELUTYX™, to develop sustained-release therapies. This technology is designed to reduce the therapeutic burden on patients by decreasing the frequency of required treatments. The company's lead product candidate, AXPAXLI™ (axitinib intravitreal implant), is in late-stage clinical development for major retinal diseases.

Recent filings

Filing Released Lang Actions
10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-05 English
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed under Item 2.02 “Results of Operations and Financial Condition” and furnishes a press release announcing the quarter-ended March 31, 2026 financial results. This is the initial announcement of quarterly results, matching the definition of an Earnings Release (ER). Q1 2026
2026-05-05 English
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 27, 2026, by Ocular Therapeutix, Inc. It announces that the company will make available slides presented at the 49th Macula Society Annual Meeting regarding clinical trial results. The document is short (3333 characters) and primarily serves as a disclosure or announcement rather than containing detailed financial data or the actual presentation itself. It does not contain financial statements or substantive financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-02-27 English
4 - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Director's Dealing
2026-02-26 English
4 - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Director's Dealing
2026-02-26 English
4 - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Director's Dealing
2026-02-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.